From Name:
From Email:
To Name:
To Email:

Optional Message:

New agent shows promise across many cancers which have TRK fusion mutations

from Cure

Larotrectinib, a novel pan-TRK inhibitor, produced response in about 75 percent of patients with a range of TRK fusion–positive solid tumors, potentially laying the groundwork for the oral agent to become standard of care for both adults and children with any advanced tumor that harbors this mutation. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063